-
公开(公告)号:US5753631A
公开(公告)日:1998-05-19
申请号:US457886
申请日:1995-05-31
IPC分类号: A61K9/127 , A61K31/70 , A61K31/715 , A61K35/12 , A61K38/13 , A61K47/48 , C07H3/06 , C07H15/04 , C07H15/10 , C07K16/18 , C12N9/10 , G01N33/569 , C07H15/00
CPC分类号: C07H15/10 , A61K31/70 , A61K31/715 , A61K47/48023 , A61K47/48046 , A61K47/48092 , A61K47/48546 , A61K47/48815 , A61K9/1271 , C07H15/04 , C07H3/06 , C07K16/18 , C12N9/1051 , G01N33/56972
摘要: The present invention is directed towards compositions and methods for reducing or controlling inflammation and for treating inflammatory disease processes and other pathological conditions mediated by intercellular adhesion. The compositions of the invention include compounds that selectively bind selectin receptors, the selectin binding activity being mediated by a carbohydrate moiety. The selectin-binding moieties of the invention are derivatives of a sialylated, fucosylated N-acetyllactosamine unit of the Lewis X antigen. Compounds containing a selectin-binding moiety in both monovalent and multivalent forms are included in the invention. The compounds of the invention are provided as pharmaceutical compositions which include, for example, liposomes that carry selectin-binding moieties of the invention. The invention further includes immunoglobulins capable of selectively binding an oligosaccharide ligand that is recognized by a selectin receptor.
摘要翻译: 本发明涉及用于减少或控制炎症和治疗由细胞间粘附介导的炎性疾病过程和其它病理状况的组合物和方法。 本发明的组合物包括选择性结合选择素受体的选择素结合活性由碳水化合物部分介导的化合物。 本发明的选择素结合部分是Lewis X抗原的唾液酸化,岩藻糖化N-乙酰基乳糖胺单元的衍生物。 包含单价和多价形式的选择蛋白结合部分的化合物包括在本发明中。 本发明的化合物作为药物组合物提供,其包括例如携带本发明选择蛋白结合部分的脂质体。 本发明还包括能够选择性结合由选择素受体识别的寡糖配体的免疫球蛋白。